Innovative Treatment Strategies in High-Risk Biochemical Recurrence: Insights From the EMBARK Trial

Video content above is prompted by the following:

1. What recent data has been shown in patients with nmCSPC and high risk of BCR?
   1. BCR: prostate-specific antigen [PSA] doubling time ≤ 9 months
   2. EMBARK study: enzalutamide +GnRH) vs GnRH monotherapy vs enzalutamide monotherapy (Freedland et al, NEJM, 2023)
      1. Patient population: nmCSPC initially treated by radical prostectomy or radiotherapy, or both, with PSA doubling time ≤ 9 months
      2. Follow-up, 60.7 months
      3. Metastasis-free survival was:
         1. 87% for enzalutamide + GnRH (HR for risk of progression or death [compared to GnRH], 0.42; 95% CI, 0.30-0.61; P < .001)
         2. 80% for enzalutamide (HR for risk of progression or death [compared to leuprolide], 0.63; 95% CI, 0.46-0.87; P = .005)
         3. 71% for leuprolide
      4. No new safety signals